TEAEs in ≥15% of patients in either arm
| Patients, n (%) . | Magrolimab, venetoclax, and azacitidine (n = 189) . | Placebo, venetoclax, and azacitidine (n = 184) . | ||
|---|---|---|---|---|
| Overall . | Grade ≥3 . | Overall . | Grade ≥3 . | |
| Any TEAE | 188 (99.5) | 184 (97.4) | 184 (100) | 179 (97.3) |
| Neutropenia∗ | 119 (63.0) | 118 (62.4) | 115 (62.5) | 111 (60.3) |
| Anemia† | 97 (51.3) | 82 (43.4) | 64 (34.8) | 48 (26.1) |
| Thrombocytopenia‡ | 79 (41.8) | 68 (36.0) | 91 (49.5) | 82 (44.6) |
| Diarrhea | 77 (40.7) | 10 (5.3) | 67 (36.4) | 1 (0.5) |
| Constipation | 72 (38.1) | 0 | 76 (41.3) | 1 (0.5) |
| Febrile neutropenia | 70 (37.0) | 63 (33.3) | 73 (39.7) | 71 (38.6) |
| Nausea | 66 (34.9) | 3 (1.6) | 60 (32.6) | 3 (1.6) |
| Pyrexia | 60 (31.7) | 4 (2.1) | 53 (28.8) | 3 (1.6) |
| Hypokalemia | 50 (26.5) | 16 (8.5) | 56 (30.4) | 11 (6.0) |
| Decreased appetite | 40 (21.2) | 5 (2.6) | 30 (16.3) | 6 (3.3) |
| Blood bilirubin increased | 36 (19.0) | 14 (7.4) | 14 (7.6) | 6 (3.3) |
| Fatigue | 35 (18.5) | 8 (4.2) | 36 (19.6) | 6 (3.3) |
| Infusion-related reaction | 35 (18.5) | 9 (4.8) | 16 (8.7) | 3 (1.6) |
| Vomiting | 31 (16.4) | 1 (0.5) | 40 (21.7) | 5 (2.7) |
| Edema peripheral | 27 (14.3) | 0 | 39 (21.2) | 1 (0.5) |
| Pneumonia | 29 (15.3) | 19 (10.1) | 26 (14.1) | 22 (12.0) |
| COVID-19 | 25 (13.2) | 7 (3.7) | 28 (15.2) | 6 (3.3) |
| Patients, n (%) . | Magrolimab, venetoclax, and azacitidine (n = 189) . | Placebo, venetoclax, and azacitidine (n = 184) . | ||
|---|---|---|---|---|
| Overall . | Grade ≥3 . | Overall . | Grade ≥3 . | |
| Any TEAE | 188 (99.5) | 184 (97.4) | 184 (100) | 179 (97.3) |
| Neutropenia∗ | 119 (63.0) | 118 (62.4) | 115 (62.5) | 111 (60.3) |
| Anemia† | 97 (51.3) | 82 (43.4) | 64 (34.8) | 48 (26.1) |
| Thrombocytopenia‡ | 79 (41.8) | 68 (36.0) | 91 (49.5) | 82 (44.6) |
| Diarrhea | 77 (40.7) | 10 (5.3) | 67 (36.4) | 1 (0.5) |
| Constipation | 72 (38.1) | 0 | 76 (41.3) | 1 (0.5) |
| Febrile neutropenia | 70 (37.0) | 63 (33.3) | 73 (39.7) | 71 (38.6) |
| Nausea | 66 (34.9) | 3 (1.6) | 60 (32.6) | 3 (1.6) |
| Pyrexia | 60 (31.7) | 4 (2.1) | 53 (28.8) | 3 (1.6) |
| Hypokalemia | 50 (26.5) | 16 (8.5) | 56 (30.4) | 11 (6.0) |
| Decreased appetite | 40 (21.2) | 5 (2.6) | 30 (16.3) | 6 (3.3) |
| Blood bilirubin increased | 36 (19.0) | 14 (7.4) | 14 (7.6) | 6 (3.3) |
| Fatigue | 35 (18.5) | 8 (4.2) | 36 (19.6) | 6 (3.3) |
| Infusion-related reaction | 35 (18.5) | 9 (4.8) | 16 (8.7) | 3 (1.6) |
| Vomiting | 31 (16.4) | 1 (0.5) | 40 (21.7) | 5 (2.7) |
| Edema peripheral | 27 (14.3) | 0 | 39 (21.2) | 1 (0.5) |
| Pneumonia | 29 (15.3) | 19 (10.1) | 26 (14.1) | 22 (12.0) |
| COVID-19 | 25 (13.2) | 7 (3.7) | 28 (15.2) | 6 (3.3) |